Knott David M Jr Buys 30,000 Shares of Pfizer Inc. (NYSE:PFE)

Knott David M Jr grew its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 13.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 254,537 shares of the biopharmaceutical company's stock after acquiring an additional 30,000 shares during the period. Pfizer comprises about 2.4% of Knott David M Jr's investment portfolio, making the stock its 7th biggest holding. Knott David M Jr's holdings in Pfizer were worth $6,753,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of PFE. Nordea Investment Management AB raised its stake in shares of Pfizer by 36.1% in the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock valued at $108,002,000 after purchasing an additional 1,080,822 shares in the last quarter. Parsons Capital Management Inc. RI increased its holdings in Pfizer by 118.7% in the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock valued at $7,820,000 after buying an additional 159,984 shares during the last quarter. NFJ Investment Group LLC raised its stake in Pfizer by 12.8% during the third quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company's stock valued at $11,129,000 after buying an additional 43,719 shares in the last quarter. Copley Financial Group Inc. bought a new position in Pfizer during the 3rd quarter worth approximately $577,000. Finally, Zacks Investment Management grew its position in shares of Pfizer by 10.9% in the 3rd quarter. Zacks Investment Management now owns 2,389,138 shares of the biopharmaceutical company's stock worth $69,142,000 after acquiring an additional 235,243 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Pfizer Stock Performance

Shares of PFE traded down $1.11 during trading hours on Friday, reaching $23.19. 37,930,874 shares of the company's stock traded hands, compared to its average volume of 39,312,347. Pfizer Inc. has a twelve month low of $23.19 and a twelve month high of $31.54. The business's fifty day simple moving average is $25.93 and its two-hundred day simple moving average is $26.81. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market capitalization of $131.49 billion, a price-to-earnings ratio of 16.46, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter last year, the company earned $0.10 EPS. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PFE. UBS Group reduced their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Bank of America reaffirmed a "neutral" rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.